Erasca, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ERAS$15.48-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(124,546) | $(161,650) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,107 | 3,805 |
| Stock-based compensation expense | 24,899 | 26,973 |
| In-process research and development expenses | 9,500 | 22,500 |
| Accretion on marketable securities, net | (5,087) | (9,590) |
| Impairment charge on operating lease assets and property and equipment | — | 4,653 |
| Impairment charge on investment in equity securities | — | 2,157 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current and long-term assets | 1,789 | (2,397) |
| Accounts payable | 513 | (1,532) |
| Accrued expenses and other current and long-term liabilities | (3,768) | 6,396 |
| Operating lease assets and liabilities, net | (1,862) | (732) |
| Net cash used in operating activities | (95,455) | (109,417) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (150,974) | (403,224) |
| Maturities of marketable securities | 261,027 | 269,325 |
| In-process research and development | (9,500) | (22,500) |
| Payment made for investment in equity securities | — | (157) |
| Purchases of property and equipment | (128) | (60) |
| Net cash provided by (used in) investing activities | 100,425 | (156,616) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in private placement, net of fees and expenses | — | 43,604 |
| Proceeds from issuance of common stock in underwritten offering, net of discounts and offering costs | — | 174,426 |
| Proceeds from issuance of common stock in ATM offering, net of commissions and expenses | — | 21,031 |
| Proceeds from the exercise of stock options | 372 | 836 |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 724 | 800 |
| Net cash provided by financing activities | 1,096 | 240,697 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 6,066 | (25,336) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 68,147 | 93,483 |
| Cash, cash equivalents, and restricted cash at end of the period | $74,213 | $68,147 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Vesting of early exercised options | $— | $465 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.